Marc Turner: VETERANSFirst, CHAMPION-AF Trial, and HI-PEITHO Trial Driving Innovation at ACC26
Marc Turner, SVP for US Corporate Accounts and Healthcare Solutions at Boston Scientific, shared on LinkedIn:
”ACC26 this past weekend put a spotlight on the progress happening across cardiovascular care.
The data was an important part of that, but so was the collaboration and effort behind it. For Boston Scientific, a few events especially stood out.
CHAMPION‑AF Trial
Adherence to anticoagulation remains a real-world challenge, and that can increase stroke risk for patients with non-valvular AF.
That is why the new CHAMPION-AF data presented at ACC and published in NEJM is so meaningful.
The CHAMPION‑AF trial met all primary and secondary safety and efficacy endpoints, studying WATCHMAN™ as a first‑line option for stroke risk reduction.
Pending regulatory, guideline, and coverage updates, these findings could triple the eligible WATCHMAN population and expand how we think about stroke risk reduction in AF.
Read the press release.
HI‑PEITHO Trial
EKOS Endovascular System plus anticoagulation (AC) demonstrated superiority to AC alone for the treatment of patients with intermediate-risk PE.
In urgent situations, every minute matters. It is great to see technology make a meaningful difference when clinicians need to act quickly and confidently.
Read the press release.
VETERANSFirst
One moment that particularly stood out at ACC 2026 was the first-ever VETERANS First Panel, which challenged us to think differently about AFib care for our nation’s Veterans.
In resource-strained environments, barriers like medication adherence, fall risk, limited staffing, anesthesia availability, and travel burden can make traditional care pathways difficult.
The panel’s message was clear.
When we think differently, we expand access to stroke risk reduction and become catalysts for innovation in AFib care delivery.
I’m proud of the teams behind this work and grateful for the trust our customers and clinical partners place in us.
There is still more to do, but weekends like this are a strong reminder of what is possible when innovation stays grounded in patient needs.”
Stay updated with Hemostasis Today.
-
Jul 6, 2026, 13:53Ney Carter Borges: Bempedoic Acid Shows a Promising VTE Signal in CLEAR Outcomes Analysis
-
Jul 6, 2026, 13:37Rachad Zayat: Acute PE Study Finds USAT Associated With Better In-Hospital Outcomes
-
Jul 6, 2026, 13:28Inna Vilshanivska: Sharing Ukraine’s Experience in Blood Donor Retention at the ISBT 2026
-
Jul 6, 2026, 13:10Arun V. J.: Did You Know A Glass Of Water is The Best Way To Retain A Blood Donor?
-
Jul 6, 2026, 13:10Javed Anees: The Hidden Power of Biotin in Modern Medicine
-
Jul 6, 2026, 12:46Saneha Anjum Shaikh: Red Cell Aliquoting – Precision in Transfusion Medicine
-
Jul 6, 2026, 12:43Jennifer Dumont: WFH 2026 Congress Highlights – Expert Insights on Hemophilia Care
-
Jul 6, 2026, 12:39Muhammad Hamza: Can Hemolysis Affect Laboratory Results?
-
Jul 6, 2026, 12:32Syed A. Rizvi: Natural Blood Thinners – What Does the Science Really Say